The use of the EQ-5D preference-based health status measure in adults with Type 2 diabetes mellitus

被引:121
作者
Janssen, M. F. [1 ]
Lubetkin, E. I. [2 ]
Sekhobo, J. P. [3 ]
Pickard, A. S. [4 ]
机构
[1] EuroQol Grp, EuroQol Execut Off, NL-3006 AK Rotterdam, Netherlands
[2] CUNY, Dept Community Hlth & Social Med, Sophie Davis Sch Biomed Educ, New York, NY 10021 USA
[3] New York State Dept Hlth, Evaluat & Anal Unit, Bur Adm & Evaluat, Div Nutr, Albany, NY USA
[4] Univ Chicago, Ctr Pharmacoecon Res, Dept Pharm Practice & Pharm Adm, Coll Pharm, Chicago, IL 60637 USA
关键词
diabetes; modelling; psychometrics; quality-of-life; QUALITY-OF-LIFE; GENERAL-POPULATION SURVEY; UTILITY VALUES; PERIPHERAL NEUROPATHY; SOCIODEMOGRAPHIC FACTORS; TREATMENT SATISFACTION; EUROQOL; PEOPLE; PAIN; RESPONSIVENESS;
D O I
10.1111/j.1464-5491.2010.03136.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
P>Background The EQ-5D is a generic preference-based health status measure that has been widely applied to measure the impact of Type 2 diabetes mellitus. This review summarizes evidence on the validity, reliability and responsiveness of the EQ-5D in studies of Type 2 diabetes and provides a catalogue of EQ-5D index scores for Type 2 diabetes and various complications and subgroups. Methods A structured search was conducted (1987-2009) using keywords relevant to Type 2 diabetes and the EQ-5D. Original research studies in Type 2 diabetes that reported EQ-5D results and/or measurement properties were included. Results Of the 59 included articles, 54 publications reported EQ-5D responses and 39 papers presented evidence on the measurement properties of the EQ-5D. Studies that reported measurement properties supported construct, convergent and discriminant validity, test-retest reliability and responsiveness of the EQ-5D in Type 2 diabetes. Several studies reported a ceiling effect for the EQ-5D and an inability to capture multiple complications was observed. EQ-5D index scores ranged from 0.20 (severe diabetic peripheral neuropathic pain) to 0.88 (general population: good HbA(1c) level). For six subgroups, sufficient studies were available to calculate pooled mean index scores (95% CI): general population 0.67 (0.59-0.75), no complications 0.76 (0.68-0.83), microvascular complications 0.73 (0.57-0.89), macrovascular complications 0.73 (0.57-0.88), diabetic peripheral neuropathic pain 0.45 (0.39-0.51) and retinopathy 0.57 (0.46-0.69). Conclusions Evidence supported validity, reliability and responsiveness of the EQ-5D in Type 2 diabetes. EQ-5D index scores associated with Type 2 diabetes and various complications can be useful for modelling health outcomes in economic evaluations of health programmes for Type 2 diabetes.
引用
收藏
页码:395 / 413
页数:19
相关论文
共 92 条
  • [1] Duloxetine for the management of diabetic peripheral neuropathic pain: Evaluation of functional outcomes
    Armstrong, David G.
    Chappell, Amy S.
    Le, Trong K.
    Kajdasz, Daniel K.
    Backonja, Miroslav
    D'Souza, Deborah N.
    Russell, James M.
    [J]. PAIN MEDICINE, 2007, 8 (05) : 410 - 418
  • [2] Using the EuroQol 5-D in the Catalan General Population: Feasibility and Construct Validity
    X. Badia
    A. Schiaffino
    J. Alonso
    M. Herdman
    [J]. Quality of Life Research, 1998, 7 (4) : 311 - 322
  • [3] Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data
    Bagust, A
    Beale, S
    [J]. HEALTH ECONOMICS, 2005, 14 (03) : 217 - 230
  • [4] An assessment of the discriminative ability of the EQ-5Dindex, SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions
    Barton, Garry R.
    Sach, Tracey H.
    Doherty, Michael
    Avery, Anthony J.
    Jenkinson, Claire
    Muir, Kenneth R.
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2008, 9 (03) : 237 - 249
  • [5] The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy-naive Type 2 diabetes: A placebo-controlled, multicentre study
    Bech, P
    Moses, R
    Gomis, R
    [J]. QUALITY OF LIFE RESEARCH, 2003, 12 (04) : 413 - 425
  • [6] An off-the-shelf help list: A comprehensive catalog of preference scores from published cost-utility analyses
    Bell, CM
    Chapman, RH
    Stone, PW
    Sandberg, EA
    Neumann, PJ
    [J]. MEDICAL DECISION MAKING, 2001, 21 (04) : 288 - 294
  • [7] Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population
    Bharmal, Murtuza
    Thomas, Joseph, III
    [J]. VALUE IN HEALTH, 2006, 9 (04) : 262 - 271
  • [8] BOWMAN L, 2006, P 23 EUROQOL PLEN M, P437
  • [9] Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes
    Boye, Kristina Secnik
    Matza, Louis S.
    Oglesby, Alan
    Malley, Karen
    Kim, Sunny
    Hayes, Risa P.
    Brodows, Robert
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2006, 4 (1)
  • [10] Trends in the measurement of health utilities in published cost-utility analyses
    Brauer, Carmen A.
    Rosen, Allison B.
    Greenberg, Dan
    Neumann, Peter J.
    [J]. VALUE IN HEALTH, 2006, 9 (04) : 213 - 218